Is Beaten-Down Summit Therapeutics Stock a Bad-News Buy?
2/6 11:23
Shares of Summit Therapeutics (NASDAQ: SMMT) tanked more than 30% on Friday, May 30. Such dramatic price swings aren't unusual in the biotechnology industry; in this case, disappointing data from an important clinical trial drove the stock down....